Sitryxto receive $50M upfront, $10M equity investment, ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop and commercialize immunometabolism targeted therapies, including Sitryx’s two lead projects
- The companies will collaborate for 5yrs.
supportingthe development of therapies with Sitryx to be responsible for drug discovery while Lilly to fund and manage the clinical & commercial activities
- The collaboration will evaluate up to four novel preclinical targets identified by
Sitryx, leading to potential therapies for autoimmune diseases
Click here to read full press release/ article | Ref: Eli Lilly | Image: Luckystep